nohavičky plienkové abri form m0
abena international a/s (bambo) egelung 35 6200 aabenraa dánsko -
vozík invalidný mechanický odľahčený start m0 basic
ottobock se & co. kg aa stammwerk, max-näder-strasse 15 d-37115 duderstadt nemecko -
bicalutamid-teva 150 mg
teva pharmaceuticals slovakia s.r.o., slovensko - bikalutamid - 44 - cytostatica
bicacel 150 mg
glenmark pharmaceuticals s.r.o., Česká republika - bikalutamid - 44 - cytostatica
bicalutamide pharmevid 150 mg
pharmevid s.r.o., slovensko - bikalutamid - 44 - cytostatica
bicagelan 150 mg filmom obalené tablety
g.l. pharma gmbh, rakúsko - bikalutamid - 44 - cytostatica
caprodez
ardez pharma, spol. s r.o., Česká republika - bikalutamid - 44 - cytostatica
bicusan 150 mg
actavis group ptc ehf., island - bikalutamid - 44 - cytostatica
binabic 150 mg
vipharm s.a., poľsko - bikalutamid - 44 - cytostatica
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatické nádory - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.